These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 18630457

  • 1. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 2. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 3. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R, Lillie T, Tomita D, Balducci L.
    Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
    [Abstract] [Full Text] [Related]

  • 4. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy.
    Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C.
    Curr Med Res Opin; 2011 Feb; 27(2):355-63. PubMed ID: 21166611
    [Abstract] [Full Text] [Related]

  • 5. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 Feb; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 6. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 8. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 9. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D, Vincenzi B, La Cesa A, Virzi V, Navajas F, Malafarina V, Dicuonzo G, Cassandro R, Esposito V, Montesarchio V, Groeger AM, Tonini G.
    Anticancer Res; 2005 May; 25(1B):669-74. PubMed ID: 15816644
    [Abstract] [Full Text] [Related]

  • 10. Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.
    Beer TM, Bergenstock M, Birt K, Higano CS.
    Clin Genitourin Cancer; 2007 Jun; 5(5):329-33. PubMed ID: 17645830
    [Abstract] [Full Text] [Related]

  • 11. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.
    Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
    [Abstract] [Full Text] [Related]

  • 12. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 13. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S, Boulton H, Gokal R.
    J Nephrol; 2004 Jun; 17(5):687-92. PubMed ID: 15593036
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
    Ichinose Y, Seto T, Nishiwaki Y, Ohe Y, Yamada Y, Takeda K, Saijo N, Hotta T.
    Jpn J Clin Oncol; 2010 Jun; 40(6):521-9. PubMed ID: 20508073
    [Abstract] [Full Text] [Related]

  • 15. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 16. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K.
    Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
    [Abstract] [Full Text] [Related]

  • 17. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D, George MJ, Harrison LB.
    Cancer; 2003 Sep 01; 98(5):1072-9. PubMed ID: 12942577
    [Abstract] [Full Text] [Related]

  • 18. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C.
    J Intern Med; 2006 Dec 01; 260(6):577-85. PubMed ID: 17116009
    [Abstract] [Full Text] [Related]

  • 19. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Bastit L, Vandebroek A, Altintas S, Gaede B, Pintér T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF.
    J Clin Oncol; 2008 Apr 01; 26(10):1611-8. PubMed ID: 18375890
    [Abstract] [Full Text] [Related]

  • 20. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T, German Aranesp Study Group.
    Nephrol Dial Transplant; 2004 May 01; 19(5):1224-30. PubMed ID: 14993489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.